Wiki source code of Neurodiagnoses
Version 26.1 by manuelmenendez on 2025/01/29 18:48
Show last authors
author | version | line-number | content |
---|---|---|---|
1 | (% class="jumbotron" %) | ||
2 | ((( | ||
3 | (% class="container" %) | ||
4 | ((( | ||
5 | = //A new tridimensional diagnostic framework for CNS diseases// = | ||
6 | |||
7 | This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. | ||
8 | We aim to create a structured, interpretable, and scalable diagnostic tool. | ||
9 | ))) | ||
10 | ))) | ||
11 | |||
12 | (% class="row" %) | ||
13 | ((( | ||
14 | (% class="col-xs-12 col-sm-8" %) | ||
15 | ((( | ||
16 | = What is this about and what can I find here? = | ||
17 | |||
18 | == **Overview** == | ||
19 | |||
20 | The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on: | ||
21 | |||
22 | * **Axis 1**: Etiology (genetic or other causes of diseases). | ||
23 | * **Axis 2**: Molecular Markers (biomarkers). | ||
24 | * **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). | ||
25 | |||
26 | This methodology enables: | ||
27 | |||
28 | * Greater precision in diagnosis. | ||
29 | * Integration of incomplete datasets using AI-driven probabilistic modeling. | ||
30 | * Stratification of patients for personalized treatment. | ||
31 | |||
32 | == **The case of neurodegenerative diseases** == | ||
33 | |||
34 | There have been described these 3 diagnostic axes: | ||
35 | |||
36 | [[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] | ||
37 | |||
38 | * ((( | ||
39 | **Axis 1: Etiology** | ||
40 | |||
41 | * //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. | ||
42 | * //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. | ||
43 | * //Tests//: Genetic testing, lifestyle, and cardiovascular screening. | ||
44 | ))) | ||
45 | * ((( | ||
46 | **Axis 2: Molecular Markers** | ||
47 | |||
48 | * //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression. | ||
49 | * //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology. | ||
50 | * //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET). | ||
51 | ))) | ||
52 | * ((( | ||
53 | **Axis 3: Neuroanatomoclinical** | ||
54 | |||
55 | * //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments. | ||
56 | * //Examples//: Hippocampal atrophy correlating with memory deficits. | ||
57 | * //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations. | ||
58 | ))) | ||
59 | |||
60 | == **Applications** == | ||
61 | |||
62 | This system enhances: | ||
63 | |||
64 | * **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials. | ||
65 | * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking. | ||
66 | |||
67 | == Who has access? == | ||
68 | |||
69 | We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! | ||
70 | |||
71 | == How to Contribute == | ||
72 | |||
73 | * Access the `/docs` folder for guidelines. | ||
74 | * Use `/code` for the latest AI pipelines. | ||
75 | * Share feedback and ideas in the wiki discussion pages. | ||
76 | |||
77 | == Key Objectives == | ||
78 | |||
79 | * Develop interpretable AI models for diagnosis and progression tracking. | ||
80 | * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources. | ||
81 | * Foster collaboration among neuroscientists, AI researchers, and clinicians. | ||
82 | ))) | ||
83 | |||
84 | |||
85 | |||
86 | |||
87 | (% class="col-xs-12 col-sm-4" %) | ||
88 | ((( | ||
89 | {{box title="**Contents**"}} | ||
90 | {{toc/}} | ||
91 | {{/box}} | ||
92 | |||
93 | == Main contents == | ||
94 | |||
95 | * `/docs`: Documentation and contribution guidelines. | ||
96 | * `/code`: Machine learning pipelines and scripts. | ||
97 | * `/data`: Sample datasets for testing. | ||
98 | * `/outputs`: Generated models, visualizations, and reports. | ||
99 | * [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]] | ||
100 | * [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]] | ||
101 | * [[to-do-list>>to-do-list]] | ||
102 | ))) | ||
103 | ))) |